Vihit Gupta

Mr. Vihit Gupta


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2025 in Genes
Verified
Journal Article
Open access
PDF file
BBBrailey Buntin
Brailey Buntin
MGMadison Guyette
Madison Guyette
VGVihit Gupta
Vihit Gupta
KIKanayo Ikeh
Kanayo Ikeh
SBSombodhi Bhattacharya
Sombodhi Bhattacharya
NCNimrat Chatterjee
Nimrat Chatterjee
Background: Genomic integrity is crucial to the cellular life cycle, which involves a tightly regulated process where cells progress through specific phases to ensure that fully replicated, undamaged DNA is inherited by daughter cells. Any dysfunction in this process or unrepaired DNA damage leads to cell cycle arrest and programmed cell death. Cancer cells are known to exploit these mechanisms to continue dividing. Usually, DNA damage arrests replication, allowing the DNA Damage Response (DDR) pathway to activate, which repairs the DNA or bypasses the damage to support cell survival and preserve genome integrity. For DNA damage bypass or translesion synthesis (TLS), a group of low-fidelity polymerases perform error-prone DNA synthesis opposite damaged bases, where REV1 functions as the main scaffolding protein. Previously, we reported non-TLS functions of REV1, including its role in triggering DNA damage-dependent specific DNA metabolic processes. Methods and Results: In this study, we demonstrate that REV1 plays a significant role in cell cycle progression and that its loss causes arrest at the G2/M phase in flow cytometry analysis. This unexpected phenotype includes dysregulation of G2/M regulators, such as Cyclin B1 and tubulins, in REV1-deficient cells compared to controls, as quantified by Western blot. Additionally, phosphorylation of histone H3 at serine 28 was significantly reduced in these REV1-deficient cells. These G2/M arrest features were even more pronounced in REV1-deficient cells treated with the tubulin inhibitor colchicine. Conclusions: Overall, this study reveals a previously unrecognized link between REV1 TLS polymerase inhibition and the G2/M cell cycle arrest.

19 August 2026 in ChemMedChem
Verified
Journal Article
Closed access
NHNoah J. Harrahill
Noah J. Harrahill
SPSeema M. Patel
Seema M. Patel
RDRadha Charan Dash
Radha Charan Dash
AZAngela M. Zaino
Angela M. Zaino
VGVihit Gupta
Vihit Gupta
M. Kyle HaddenM. Kyle Hadden
M. Kyle Hadden

4 August 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ELErica N. Lamkin
Erica N. Lamkin
JRJessica Reich
Jessica Reich
JVJosh A. Victor
Josh A. Victor
MGMadison Guyette
Madison Guyette
NKNaveen Kothandaraman
Naveen Kothandaraman
NCNimrat Chatterjee
Nimrat Chatterjee
The molecular mechanisms behind Dengue virus-dependent host pathogenesis, especially genome instability, remain largely unclear. This RNA virus causes a debilitating disease during active infection and presents future risks of postdengue syndromes, leukemia, and DNA damage in the blood cells of infected patients, with the underlying mechanisms unknown. In this study, we show that DENV-4 infection induces significant DNA damage and suppresses the transcription of genes involved in DNA repair and select mutagenic translesion synthesis (TLS) polymerases, indicating that DENV-4-dependent pathobiology leaves durable biological “scars” that incrementally increase chronic disease risk, including carcinogenesis and postdengue syndromes.

6 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
VGVihit Gupta
Vihit Gupta
MGMadison Guyette
Madison Guyette
SBSombodhi Bhattacharya
Sombodhi Bhattacharya
JVJoshua A. Victor
Joshua A. Victor
NKNaveen Kothandaraman
Naveen Kothandaraman
NCNimrat Chatterjee
Nimrat Chatterjee
Translesion synthesis (TLS) promotes DNA damage tolerance and contributes to chemotherapy resistance by enabling replication across damaged DNA templates. REV1, a central TLS regulator, is a potential therapeutic target to enhance the efficacy of genotoxic chemotherapy. Here, we investigated the therapeutic consequences of pharmacologic and genetic REV1 targeting in colorectal cancer (CRC) and evaluated the sensitivity of patient-derived CRC organoids to the REV1 inhibitor JH-RE-06. JH-RE-06 enhanced oxaliplatin sensitivity in HCT116 cells and 5-fluorouracil (5-FU) sensitivity in HT-29 cells, whereas reciprocal combinations produced limited sensitization, indicating treatment-and cellular context-dependent responses. siRNA-mediated REV1 depletion similarly enhanced chemotherapy sensitivity, supporting REV1 involvement in these responses. MNNG sensitivity assays and MLH1 expression analyses did not reveal consistent treatment-associated changes in mismatch repair function, while targeted HPRT1 sequencing identified no detectable sequence alterations in the region examined. Chemosensitization was not accompanied by consistent increases in caspase-3/7 activation under the conditions tested. REV1 inhibition also caused LC3-II accumulation and, after prolonged inhibitor exposure, reduced β-tubulin abundance, indicating additional autophagy-associated and cytoskeletal responses. In two patient-derived CRC organoid models, JH-RE-06 exhibited single-agent growth-inhibitory activity, with mean IC50 values of 2.01 and 1.4 µM, respectively. Together, these findings demonstrate context-dependent chemosensitization and organoid growth inhibition following REV1 targeting, suggesting that its therapeutic consequences may extend beyond canonical TLS-mediated DNA damage tolerance. SIGNIFICANCE STATEMENT: Targeting REV1 enhances sensitivity to specific chemotherapeutic agents in colorectal cancer cells and inhibits growth of patient-derived colorectal cancer organoids. REV1 inhibition is also accompanied by LC3-II accumulation and reduced β-tubulin abundance, revealing cellular responses beyond conventional measures of DNA damage and mutagenesis. These findings identify treatment-dependent therapeutic vulnerabilities and suggest that the consequences of REV1 targeting may extend beyond its established role in translesion synthesis, supporting further investigation of REV1-directed therapeutic strategies in colorectal cancer. CLINICAL TRANSLATION RELEVANCE: Chemotherapy resistance remains a major obstacle to effective treatment of colorectal cancer (CRC). This study identifies REV1 as a potential therapeutic target, showing that pharmacologic and genetic REV1 targeting enhances oxaliplatin sensitivity in HCT116 cells and 5-fluorouracil (5-FU) sensitivity in HT-29 cells, while reciprocal combinations show limited additional sensitization. Furthermore, patient-derived CRC organoids demonstrate single-agent sensitivity to REV1 inhibition at low-micromolar concentrations, supporting its activity across distinct tumor-derived models. REV1 inhibition is also associated with LC3-II accumulation and reduced β-tubulin abundance, suggesting additional cellular responses that may influence therapeutic outcomes. Together, these findings provide a preclinical rationale for investigating REV1-directed therapies in CRC and underscore the importance of identifying tumor-specific determinants of chemotherapy response and sensitivity to REV1 inhibition. Graphical Graphical abstract. Schematic representation of REV1 targeting and treatment-dependent chemosensitization in colorectal cancer Pharmacologic inhibition of REV1 using JH-RE-06 disrupts its interaction with polymerase ζ (POL ζ) and selectively enhances chemotherapy sensitivity in colorectal cancer (CRC) cells. REV1 inhibition increases sensitivity to 5-fluorouracil (5-FU) in mismatch repair-proficient (pMMR) HT-29 cells and to oxaliplatin in mismatch repair-deficient (dMMR) HCT116 cells, resulting in reduced clonogenic survival. REV1 inhibition is accompanied by increased LC3-II abundance and reduced β-tubulin expression, indicating autophagy-associated and cytoskeletal changes. Assays of mismatch repair-associated responses, HPRT mutagenesis, DNA damage, and apoptosis did not identify a consistent mechanism explaining the differential chemosensitization. JH-RE-06 also exhibits single-agent growth-inhibitory activity in patient-derived CRC organoids. Together, these findings highlight treatment-dependent therapeutic vulnerabilities associated with REV1 targeting in CRC.